Omeprazole and PGC-Formulated Heparin Binding Epidermal Growth Factor Normalizes Fasting Blood Glucose and Suppresses Insulitis in Multiple Low Dose Streptozotocin Diabetes Model
ABSTRACT Purpose Our objective was to develop novel nanocarriers (protected graft copolymer, PGC) that improve the stability of heparin binding EGF (HBEGF) and gastrin and then to use PGC-formulated HBEGF (PGC-HBEGF) and Omeprazole (+/− PGC-gastrin) for normalizing fasting blood glucose (FBG) and im...
Gespeichert in:
| Veröffentlicht in: | Pharmaceutical research 2013-11, Vol.30 (11), p.2843-2854 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2854 |
|---|---|
| container_issue | 11 |
| container_start_page | 2843 |
| container_title | Pharmaceutical research |
| container_volume | 30 |
| creator | Castillo, Gerardo M. Nishimoto-Ashfield, Akiko Banerjee, Aryamitra A. Landolfi, Jennifer A. Lyubimov, Alexander V. Bolotin, Elijah M. |
| description | ABSTRACT
Purpose
Our objective was to develop novel nanocarriers (protected graft copolymer, PGC) that improve the stability of heparin binding EGF (HBEGF) and gastrin and then to use PGC-formulated HBEGF (PGC-HBEGF) and Omeprazole (+/− PGC-gastrin) for normalizing fasting blood glucose (FBG) and improving islet function in diabetic mice.
Methods
HBEGF, PGC-HBEGF, Omeprazole, Omeprazole + PGC-HBEGF, Omeprazole + PGC-gastrin + PGC-HBEGF and epidermal growth factor (EGF) + gastrin were tested in multiple low dose streptozotocin diabetic mice.
Results
Omeprazole + PGC-HBEGF normalized FBG and is better than EGF + gastrin at improving islet function and decreasing insulitis. Groups treated with Omeprazole, Omeprazole + PGC-HBEGF, or EGF + gastrin have significantly improved islet function
versus
saline control. All animals that received PGC-HBEGF had significantly reduced islet insulitis
versus
saline control. Non-FBG was lower for Omeprazole + PGC-gastrin + PGC-HBEGF but Omeprazole + PGC-HBEGF alone showed better FBG and glucose tolerance.
Conclusions
Omeprazole + PGC-HBEGF provides a sustained exposure to both EGFRA and gastrin, improves islet function, and decreases insulitis in multiple low dose streptozotocin diabetic mice. Although HBEGF or EGF elevates non-FBG, it facilitates a reduction of insulitis and, in the presence of Omeprazole, provides normalization of FBG at the end of treatment. The study demonstrates Omeprazole and PGC-HBEGF is a viable treatment for diabetes. |
| doi_str_mv | 10.1007/s11095-013-1112-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1442359547</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3100644081</sourcerecordid><originalsourceid>FETCH-LOGICAL-c445t-b0e084bc0fd1c76becdb01fee59a1984db07c25194338c510cfc89a66f95f9553</originalsourceid><addsrcrecordid>eNp1kd1u1DAQhS0EokvhAbhBlhCXAU9iJ_El3Xa3lbYUqSBxFznOpLjyxqntqGIfiyfEUZafGyRLlsffnDOaQ8hrYO-BsepDAGBSZAyKDADyrHxCViCqIpOMf3tKVqzKeVZXHE7IixDuGWM1SP6cnORFJQspYUV-3uxx9OrgLFI1dPTzdp1tnN9PVkXs6CWOypuBnpmhM8MdvRhNh36vLN169xi_043S0Xn6yc1Fc8CQKiHO6Jl1rqNbO2kXFu3baRw9hpCgqyFM1kQTaBK_nmw0Yxpg5x7p-UzfRo9jdAcXnU7AuVEtxtR27Tq0L8mzXtmAr473Kfm6ufiyvsx2N9ur9cddpjkXMWsZspq3mvUd6KpsUXctgx5RSAWy5ulV6VykhRRFrQUw3etaqrLspUhHFKfk7aI7evcwYYjNvZv8kCwb4DwvhBS8ShQslPYuBI99M3qzV_5HA6yZU2qWlJqUUjOn1JSp581ReWr32P3p-B1LAt4dARW0sr1XgzbhL1fVZV3Us3m-cCF9DXfo_xnxv-6_ACQqrU4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1442359547</pqid></control><display><type>article</type><title>Omeprazole and PGC-Formulated Heparin Binding Epidermal Growth Factor Normalizes Fasting Blood Glucose and Suppresses Insulitis in Multiple Low Dose Streptozotocin Diabetes Model</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Castillo, Gerardo M. ; Nishimoto-Ashfield, Akiko ; Banerjee, Aryamitra A. ; Landolfi, Jennifer A. ; Lyubimov, Alexander V. ; Bolotin, Elijah M.</creator><creatorcontrib>Castillo, Gerardo M. ; Nishimoto-Ashfield, Akiko ; Banerjee, Aryamitra A. ; Landolfi, Jennifer A. ; Lyubimov, Alexander V. ; Bolotin, Elijah M.</creatorcontrib><description>ABSTRACT
Purpose
Our objective was to develop novel nanocarriers (protected graft copolymer, PGC) that improve the stability of heparin binding EGF (HBEGF) and gastrin and then to use PGC-formulated HBEGF (PGC-HBEGF) and Omeprazole (+/− PGC-gastrin) for normalizing fasting blood glucose (FBG) and improving islet function in diabetic mice.
Methods
HBEGF, PGC-HBEGF, Omeprazole, Omeprazole + PGC-HBEGF, Omeprazole + PGC-gastrin + PGC-HBEGF and epidermal growth factor (EGF) + gastrin were tested in multiple low dose streptozotocin diabetic mice.
Results
Omeprazole + PGC-HBEGF normalized FBG and is better than EGF + gastrin at improving islet function and decreasing insulitis. Groups treated with Omeprazole, Omeprazole + PGC-HBEGF, or EGF + gastrin have significantly improved islet function
versus
saline control. All animals that received PGC-HBEGF had significantly reduced islet insulitis
versus
saline control. Non-FBG was lower for Omeprazole + PGC-gastrin + PGC-HBEGF but Omeprazole + PGC-HBEGF alone showed better FBG and glucose tolerance.
Conclusions
Omeprazole + PGC-HBEGF provides a sustained exposure to both EGFRA and gastrin, improves islet function, and decreases insulitis in multiple low dose streptozotocin diabetic mice. Although HBEGF or EGF elevates non-FBG, it facilitates a reduction of insulitis and, in the presence of Omeprazole, provides normalization of FBG at the end of treatment. The study demonstrates Omeprazole and PGC-HBEGF is a viable treatment for diabetes.</description><identifier>ISSN: 0724-8741</identifier><identifier>EISSN: 1573-904X</identifier><identifier>DOI: 10.1007/s11095-013-1112-6</identifier><identifier>PMID: 23793991</identifier><identifier>CODEN: PHREEB</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Animals ; Biochemistry ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedical Engineering and Bioengineering ; Biomedicine ; Blood Glucose - analysis ; Copolymers ; Diabetes ; Diabetes Mellitus, Experimental - drug therapy ; Diabetes Mellitus, Experimental - pathology ; Diabetes. Impaired glucose tolerance ; Drug Carriers - chemistry ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Epidermal growth factor ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Gastrins - administration & dosage ; Gastrins - pharmacokinetics ; Gastrins - therapeutic use ; Glucose ; Heparin-binding EGF-like Growth Factor ; Intercellular Signaling Peptides and Proteins - administration & dosage ; Intercellular Signaling Peptides and Proteins - pharmacokinetics ; Intercellular Signaling Peptides and Proteins - therapeutic use ; Male ; Medical Law ; Medical sciences ; Mice ; Nanostructures - chemistry ; Omeprazole - administration & dosage ; Omeprazole - pharmacokinetics ; Omeprazole - therapeutic use ; Pancreas - drug effects ; Pancreas - pathology ; Pharmacology ; Pharmacology. Drug treatments ; Pharmacology/Toxicology ; Pharmacy ; Polymers - chemistry ; Research Paper ; Streptozocin</subject><ispartof>Pharmaceutical research, 2013-11, Vol.30 (11), p.2843-2854</ispartof><rights>Springer Science+Business Media New York 2013</rights><rights>2014 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c445t-b0e084bc0fd1c76becdb01fee59a1984db07c25194338c510cfc89a66f95f9553</citedby><cites>FETCH-LOGICAL-c445t-b0e084bc0fd1c76becdb01fee59a1984db07c25194338c510cfc89a66f95f9553</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11095-013-1112-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11095-013-1112-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27868387$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23793991$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Castillo, Gerardo M.</creatorcontrib><creatorcontrib>Nishimoto-Ashfield, Akiko</creatorcontrib><creatorcontrib>Banerjee, Aryamitra A.</creatorcontrib><creatorcontrib>Landolfi, Jennifer A.</creatorcontrib><creatorcontrib>Lyubimov, Alexander V.</creatorcontrib><creatorcontrib>Bolotin, Elijah M.</creatorcontrib><title>Omeprazole and PGC-Formulated Heparin Binding Epidermal Growth Factor Normalizes Fasting Blood Glucose and Suppresses Insulitis in Multiple Low Dose Streptozotocin Diabetes Model</title><title>Pharmaceutical research</title><addtitle>Pharm Res</addtitle><addtitle>Pharm Res</addtitle><description>ABSTRACT
Purpose
Our objective was to develop novel nanocarriers (protected graft copolymer, PGC) that improve the stability of heparin binding EGF (HBEGF) and gastrin and then to use PGC-formulated HBEGF (PGC-HBEGF) and Omeprazole (+/− PGC-gastrin) for normalizing fasting blood glucose (FBG) and improving islet function in diabetic mice.
Methods
HBEGF, PGC-HBEGF, Omeprazole, Omeprazole + PGC-HBEGF, Omeprazole + PGC-gastrin + PGC-HBEGF and epidermal growth factor (EGF) + gastrin were tested in multiple low dose streptozotocin diabetic mice.
Results
Omeprazole + PGC-HBEGF normalized FBG and is better than EGF + gastrin at improving islet function and decreasing insulitis. Groups treated with Omeprazole, Omeprazole + PGC-HBEGF, or EGF + gastrin have significantly improved islet function
versus
saline control. All animals that received PGC-HBEGF had significantly reduced islet insulitis
versus
saline control. Non-FBG was lower for Omeprazole + PGC-gastrin + PGC-HBEGF but Omeprazole + PGC-HBEGF alone showed better FBG and glucose tolerance.
Conclusions
Omeprazole + PGC-HBEGF provides a sustained exposure to both EGFRA and gastrin, improves islet function, and decreases insulitis in multiple low dose streptozotocin diabetic mice. Although HBEGF or EGF elevates non-FBG, it facilitates a reduction of insulitis and, in the presence of Omeprazole, provides normalization of FBG at the end of treatment. The study demonstrates Omeprazole and PGC-HBEGF is a viable treatment for diabetes.</description><subject>Animals</subject><subject>Biochemistry</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedical Engineering and Bioengineering</subject><subject>Biomedicine</subject><subject>Blood Glucose - analysis</subject><subject>Copolymers</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Experimental - drug therapy</subject><subject>Diabetes Mellitus, Experimental - pathology</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Drug Carriers - chemistry</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Epidermal growth factor</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Gastrins - administration & dosage</subject><subject>Gastrins - pharmacokinetics</subject><subject>Gastrins - therapeutic use</subject><subject>Glucose</subject><subject>Heparin-binding EGF-like Growth Factor</subject><subject>Intercellular Signaling Peptides and Proteins - administration & dosage</subject><subject>Intercellular Signaling Peptides and Proteins - pharmacokinetics</subject><subject>Intercellular Signaling Peptides and Proteins - therapeutic use</subject><subject>Male</subject><subject>Medical Law</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Nanostructures - chemistry</subject><subject>Omeprazole - administration & dosage</subject><subject>Omeprazole - pharmacokinetics</subject><subject>Omeprazole - therapeutic use</subject><subject>Pancreas - drug effects</subject><subject>Pancreas - pathology</subject><subject>Pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacy</subject><subject>Polymers - chemistry</subject><subject>Research Paper</subject><subject>Streptozocin</subject><issn>0724-8741</issn><issn>1573-904X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kd1u1DAQhS0EokvhAbhBlhCXAU9iJ_El3Xa3lbYUqSBxFznOpLjyxqntqGIfiyfEUZafGyRLlsffnDOaQ8hrYO-BsepDAGBSZAyKDADyrHxCViCqIpOMf3tKVqzKeVZXHE7IixDuGWM1SP6cnORFJQspYUV-3uxx9OrgLFI1dPTzdp1tnN9PVkXs6CWOypuBnpmhM8MdvRhNh36vLN169xi_043S0Xn6yc1Fc8CQKiHO6Jl1rqNbO2kXFu3baRw9hpCgqyFM1kQTaBK_nmw0Yxpg5x7p-UzfRo9jdAcXnU7AuVEtxtR27Tq0L8mzXtmAr473Kfm6ufiyvsx2N9ur9cddpjkXMWsZspq3mvUd6KpsUXctgx5RSAWy5ulV6VykhRRFrQUw3etaqrLspUhHFKfk7aI7evcwYYjNvZv8kCwb4DwvhBS8ShQslPYuBI99M3qzV_5HA6yZU2qWlJqUUjOn1JSp581ReWr32P3p-B1LAt4dARW0sr1XgzbhL1fVZV3Us3m-cCF9DXfo_xnxv-6_ACQqrU4</recordid><startdate>20131101</startdate><enddate>20131101</enddate><creator>Castillo, Gerardo M.</creator><creator>Nishimoto-Ashfield, Akiko</creator><creator>Banerjee, Aryamitra A.</creator><creator>Landolfi, Jennifer A.</creator><creator>Lyubimov, Alexander V.</creator><creator>Bolotin, Elijah M.</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20131101</creationdate><title>Omeprazole and PGC-Formulated Heparin Binding Epidermal Growth Factor Normalizes Fasting Blood Glucose and Suppresses Insulitis in Multiple Low Dose Streptozotocin Diabetes Model</title><author>Castillo, Gerardo M. ; Nishimoto-Ashfield, Akiko ; Banerjee, Aryamitra A. ; Landolfi, Jennifer A. ; Lyubimov, Alexander V. ; Bolotin, Elijah M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c445t-b0e084bc0fd1c76becdb01fee59a1984db07c25194338c510cfc89a66f95f9553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Animals</topic><topic>Biochemistry</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedical Engineering and Bioengineering</topic><topic>Biomedicine</topic><topic>Blood Glucose - analysis</topic><topic>Copolymers</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Experimental - drug therapy</topic><topic>Diabetes Mellitus, Experimental - pathology</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Drug Carriers - chemistry</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Epidermal growth factor</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Gastrins - administration & dosage</topic><topic>Gastrins - pharmacokinetics</topic><topic>Gastrins - therapeutic use</topic><topic>Glucose</topic><topic>Heparin-binding EGF-like Growth Factor</topic><topic>Intercellular Signaling Peptides and Proteins - administration & dosage</topic><topic>Intercellular Signaling Peptides and Proteins - pharmacokinetics</topic><topic>Intercellular Signaling Peptides and Proteins - therapeutic use</topic><topic>Male</topic><topic>Medical Law</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Nanostructures - chemistry</topic><topic>Omeprazole - administration & dosage</topic><topic>Omeprazole - pharmacokinetics</topic><topic>Omeprazole - therapeutic use</topic><topic>Pancreas - drug effects</topic><topic>Pancreas - pathology</topic><topic>Pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacy</topic><topic>Polymers - chemistry</topic><topic>Research Paper</topic><topic>Streptozocin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Castillo, Gerardo M.</creatorcontrib><creatorcontrib>Nishimoto-Ashfield, Akiko</creatorcontrib><creatorcontrib>Banerjee, Aryamitra A.</creatorcontrib><creatorcontrib>Landolfi, Jennifer A.</creatorcontrib><creatorcontrib>Lyubimov, Alexander V.</creatorcontrib><creatorcontrib>Bolotin, Elijah M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Pharmaceutical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Castillo, Gerardo M.</au><au>Nishimoto-Ashfield, Akiko</au><au>Banerjee, Aryamitra A.</au><au>Landolfi, Jennifer A.</au><au>Lyubimov, Alexander V.</au><au>Bolotin, Elijah M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Omeprazole and PGC-Formulated Heparin Binding Epidermal Growth Factor Normalizes Fasting Blood Glucose and Suppresses Insulitis in Multiple Low Dose Streptozotocin Diabetes Model</atitle><jtitle>Pharmaceutical research</jtitle><stitle>Pharm Res</stitle><addtitle>Pharm Res</addtitle><date>2013-11-01</date><risdate>2013</risdate><volume>30</volume><issue>11</issue><spage>2843</spage><epage>2854</epage><pages>2843-2854</pages><issn>0724-8741</issn><eissn>1573-904X</eissn><coden>PHREEB</coden><abstract>ABSTRACT
Purpose
Our objective was to develop novel nanocarriers (protected graft copolymer, PGC) that improve the stability of heparin binding EGF (HBEGF) and gastrin and then to use PGC-formulated HBEGF (PGC-HBEGF) and Omeprazole (+/− PGC-gastrin) for normalizing fasting blood glucose (FBG) and improving islet function in diabetic mice.
Methods
HBEGF, PGC-HBEGF, Omeprazole, Omeprazole + PGC-HBEGF, Omeprazole + PGC-gastrin + PGC-HBEGF and epidermal growth factor (EGF) + gastrin were tested in multiple low dose streptozotocin diabetic mice.
Results
Omeprazole + PGC-HBEGF normalized FBG and is better than EGF + gastrin at improving islet function and decreasing insulitis. Groups treated with Omeprazole, Omeprazole + PGC-HBEGF, or EGF + gastrin have significantly improved islet function
versus
saline control. All animals that received PGC-HBEGF had significantly reduced islet insulitis
versus
saline control. Non-FBG was lower for Omeprazole + PGC-gastrin + PGC-HBEGF but Omeprazole + PGC-HBEGF alone showed better FBG and glucose tolerance.
Conclusions
Omeprazole + PGC-HBEGF provides a sustained exposure to both EGFRA and gastrin, improves islet function, and decreases insulitis in multiple low dose streptozotocin diabetic mice. Although HBEGF or EGF elevates non-FBG, it facilitates a reduction of insulitis and, in the presence of Omeprazole, provides normalization of FBG at the end of treatment. The study demonstrates Omeprazole and PGC-HBEGF is a viable treatment for diabetes.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>23793991</pmid><doi>10.1007/s11095-013-1112-6</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0724-8741 |
| ispartof | Pharmaceutical research, 2013-11, Vol.30 (11), p.2843-2854 |
| issn | 0724-8741 1573-904X |
| language | eng |
| recordid | cdi_proquest_journals_1442359547 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Animals Biochemistry Biological and medical sciences Biomedical and Life Sciences Biomedical Engineering and Bioengineering Biomedicine Blood Glucose - analysis Copolymers Diabetes Diabetes Mellitus, Experimental - drug therapy Diabetes Mellitus, Experimental - pathology Diabetes. Impaired glucose tolerance Drug Carriers - chemistry Endocrine pancreas. Apud cells (diseases) Endocrinopathies Epidermal growth factor Etiopathogenesis. Screening. Investigations. Target tissue resistance Gastrins - administration & dosage Gastrins - pharmacokinetics Gastrins - therapeutic use Glucose Heparin-binding EGF-like Growth Factor Intercellular Signaling Peptides and Proteins - administration & dosage Intercellular Signaling Peptides and Proteins - pharmacokinetics Intercellular Signaling Peptides and Proteins - therapeutic use Male Medical Law Medical sciences Mice Nanostructures - chemistry Omeprazole - administration & dosage Omeprazole - pharmacokinetics Omeprazole - therapeutic use Pancreas - drug effects Pancreas - pathology Pharmacology Pharmacology. Drug treatments Pharmacology/Toxicology Pharmacy Polymers - chemistry Research Paper Streptozocin |
| title | Omeprazole and PGC-Formulated Heparin Binding Epidermal Growth Factor Normalizes Fasting Blood Glucose and Suppresses Insulitis in Multiple Low Dose Streptozotocin Diabetes Model |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T17%3A37%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Omeprazole%20and%20PGC-Formulated%20Heparin%20Binding%20Epidermal%20Growth%20Factor%20Normalizes%20Fasting%20Blood%20Glucose%20and%20Suppresses%20Insulitis%20in%20Multiple%20Low%20Dose%20Streptozotocin%20Diabetes%20Model&rft.jtitle=Pharmaceutical%20research&rft.au=Castillo,%20Gerardo%20M.&rft.date=2013-11-01&rft.volume=30&rft.issue=11&rft.spage=2843&rft.epage=2854&rft.pages=2843-2854&rft.issn=0724-8741&rft.eissn=1573-904X&rft.coden=PHREEB&rft_id=info:doi/10.1007/s11095-013-1112-6&rft_dat=%3Cproquest_cross%3E3100644081%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1442359547&rft_id=info:pmid/23793991&rfr_iscdi=true |